Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) investors are overwhelmingly excited after the drug maker announced today that it has entered into a definitive asset purchase, …
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) partner Braeburn Pharmaceuticals announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding …
Healthcare analysts weigh in today on Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Relypsa Inc (NASDAQ:RLYP), as shares of both pharma companies took off following FDA announcements.
QUALCOMM, Inc. (NASDAQ:QCOM) is up over 1% in pre-market trading following an upgrade by Susquehanna analyst Chris Caso.
In a research report published Friday, Roth Capital analyst Scott Henry reiterated a Buy rating on shares of Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP), while raising the …
Roth Capital analyst Scott Henry came out with a favorable report on Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP), maintaining a Buy rating on the stock with a …
Titan Pharmaceuticals, Inc. (OTC MKTS:TTNP)’s implantable device for the treatment of opioid addiction performed as well as standard sublingual buprenorphine tablets in a phase …
It’s an exciting week ahead for the biotech and technology sectors as three big players are scheduled to announce their quarterly financial results. …
Titan Pharmaceuticals (OTCBB: TTNP) is a biomedical pharmaceutical company most known for its flagship drug, Probuphine, used to treat opioid addiction. Probuphine has proved …
In a research report released today, Roth Capital analyst Scott Henry initiated coverage on shares of Titan Pharmaceuticals (OTC:TTNP) with a $1.25 price target, which represents …
